Literature DB >> 24342027

Multiple sclerosis: lessons from molecular neuropathology.

Hans Lassmann1.   

Abstract

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, which leads to widespread focal lesions of primary demyelination with variable axonal, neuronal and astroglia injury. The mechanisms responsible for tissue injury in the MS brain and spinal cord are only incompletely understood. In this review we discuss that the formation of confluent subpial cortical lesions is the most specific type of tissue damage, which is exclusively present in MS patients. Current data suggest that subpial demyelination is triggered by a soluble factor, which is produced in meningeal inflammatory infiltrates and diffuses into the cortical parenchyma, where it destroys myelin either directly or indirectly through microglia activation. The presence of demyelinating activity in sera and cerebrospinal fluid of MS patients is known for decades, but the molecular nature of the possibly underlying demyelinating factor is still unclear. Destruction of myelin sheaths and oligodendrocytes as well as neurodegeneration in MS are associated with massive oxidative stress and mitochondrial injury. Oxidative stress appears to be driven in early MS by activated microglia and oxidative burst and is, in the progressive stage of the disease, amplified by additional factors related to the age of patients and accumulation of pre-existing brain damage. Thus, the demyelinating factor in MS patients may either be a currently unknown cytokine or an inflammatory mediator or, alternatively, a mixture of cytokines. It may activate microglia towards uncontrolled oxygen radical production. Alternatively, the demyelinating factor may by itself trigger demyelination, which is then amplified by oxidative injury. The molecular characterization of the demyelinating factor may provide an important clue for the understanding of MS pathogenesis in the future.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Demyelination; Multiple sclerosis; Neurodegeneration

Mesh:

Year:  2013        PMID: 24342027     DOI: 10.1016/j.expneurol.2013.12.003

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  43 in total

1.  Heterogeneity of Cortical Lesion Susceptibility Mapping in Multiple Sclerosis.

Authors:  M Castellaro; R Magliozzi; A Palombit; M Pitteri; E Silvestri; V Camera; S Montemezzi; F B Pizzini; A Bertoldo; R Reynolds; S Monaco; M Calabrese
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

Review 2.  Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Authors:  Ai-Lan Nguyen; Melissa Gresle; Tessa Marshall; Helmut Butzkueven; Judith Field
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

3.  Metabolic voxel-based analysis of the complete human brain using fast 3D-MRSI: Proof of concept in multiple sclerosis.

Authors:  Maxime Donadieu; Yann Le Fur; Angèle Lecocq; Andrew A Maudsley; Soraya Gherib; Elisabeth Soulier; Sylviane Confort-Gouny; Fanelly Pariollaud; Marie-Pierre Ranjeva; Jean Pelletier; Maxime Guye; Wafaa Zaaraoui; Bertrand Audoin; Jean-Philippe Ranjeva
Journal:  J Magn Reson Imaging       Date:  2016-01-12       Impact factor: 4.813

4.  Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis.

Authors:  Zheng Liu; Matteo Pardini; Özgür Yaldizli; Varun Sethi; Nils Muhlert; Claudia A M Wheeler-Kingshott; Rebecca S Samson; David H Miller; Declan T Chard
Journal:  Brain       Date:  2015-03-29       Impact factor: 13.501

5.  Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis.

Authors:  Nicole Trager; Amena Smith; Gerald Wallace Iv; Mitsuyoshi Azuma; Jun Inoue; Craig Beeson; Azizul Haque; Naren L Banik
Journal:  J Neurochem       Date:  2014-02-12       Impact factor: 5.372

Review 6.  The immunogenetics of multiple sclerosis: A comprehensive review.

Authors:  Jill A Hollenbach; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2015-07-02       Impact factor: 7.094

7.  Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study.

Authors:  Paolo Riccio; Rocco Rossano; Marilena Larocca; Vincenzo Trotta; Ilario Mennella; Paola Vitaglione; Michele Ettorre; Antonio Graverini; Alessandro De Santis; Elisabetta Di Monte; Maria Gabriella Coniglio
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-18

8.  Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease.

Authors:  Christina J Azevedo; Steven Y Cen; Sankalpa Khadka; Shuang Liu; John Kornak; Yonggang Shi; Ling Zheng; Stephen L Hauser; Daniel Pelletier
Journal:  Ann Neurol       Date:  2018-02-09       Impact factor: 10.422

9.  HLA-DRB1*15 influences the development of brain tissue damage in early PPMS.

Authors:  Carmen Tur; Sreeram Ramagopalan; Daniel R Altmann; Benedetta Bodini; Mara Cercignani; Zhaleh Khaleeli; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Neurology       Date:  2014-10-08       Impact factor: 9.910

Review 10.  Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications.

Authors:  Tyrell J Simkins; Greg J Duncan; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2021-04-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.